May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
A Method to Coregister Pathology From Spectral Domain OCT With Conventional Retinal Testing
Author Affiliations & Notes
  • M. Stopa
    Ophthalmology, Poznan University of Medical Sciences, Poznan, Poland
  • B.A. Bower
    Department of Biomedical Engineering,
    Duke University, Durham, NC
  • J.A. Izatt
    Department of Biomedical Engineering,
    Duke University, Durham, NC
  • C.A. Toth
    Duke Eye Center,
    Duke University, Durham, NC
  • Footnotes
    Commercial Relationships  M. Stopa, co–inventor on a patent application, P; B.A. Bower, Bioptigen, F; Bioptigen, I; co–inventor on a patent application, P; J.A. Izatt, Bioptigen, F; Bioptigen, I; C.A. Toth, co–inventor on a patent application, P; Dr. Toth receives royalties through Duke University Patent Policy for technology licensed by Duke to Alcon, P.
  • Footnotes
    Support  NIH grants EYI3015 and EY013516, The Edward L. Grayson Retinal Research Fund, West Orange, NJ
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 4057. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Stopa, B.A. Bower, J.A. Izatt, C.A. Toth; A Method to Coregister Pathology From Spectral Domain OCT With Conventional Retinal Testing . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4057.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : We present a method to annotate, extract or preserve pathological changes recognized on a series of two dimensional SD–OCT B–scans so that the findings are maintained (visible) in an en face projection produced with SVP technique.

Methods: : Spectral domain OCT imaging of a 10 mm by 10 mm blocks of retina were obtained in subjects with neovascular and non–neovascular AMD using an SD–OCT. The image datasets consisted of 100 two dimensional B–scans exported from commercial capture software (Bioptigen, RTP, NC) into ImageJ software. The location of pathology was marked manually by an examiner on the SD–OCT cross sectional scans: margin of choroidal neovascularization at the retinal pigment epithelium (red), cystoid macular edema (yellow), macular edema without cysts (green), margins of atrophy (brown), drusen (purple) and subretinal fluid (blue). The three–dimensional blocks were then flattened creating the summed voxel projection (SVP) which retained these color landmarks of pathology relative to retinal vascular landmarks. The en face image with preserved color markings were superimposed on fluorescein angiography, autofluorescence or microperimetry images using vascular landmarks.

Results: : Retinal pathology correlated with some of the ophthalmic tests. Early hyperfluorescence on FA corresponded with choroidal neovascularization on SD–OCT. Subretinal fluid was not visible in fluorescein angiograms at six minutes and did not correspond with diminished retinal sensitivity. In contrast macular edema on SD–OCT corresponded closely with areas of no response to the brightest Goldmann 3 stimulus on microperimetry.

Conclusions: : This novel analysis technique preserves location of pathology from OCT onto flattened two dimensional images which are corregistered with en face ophthalmic tests (e.g microperimetry, autofluorescence, fluorescein angiography). This technique combines the best of OCT, high resolution, in vivo imaging of pathology with other clinically relevant data.

Keywords: imaging/image analysis: clinical • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • retina 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.